Study library
Every menopause supplement study we used
79 trials, reviews and position statements behind our grades. Each one has a plain-English summary, the dose and duration, the result compared with placebo, who funded it, and a link to PubMed or the source.
Last updated
At a glance: by our reading of the funding statements, 19 of the 79 entries are linked to a manufacturer or ingredient supplier, 34 are independent or academic, and 25 do not state funding in the abstract. Independent, publicly funded trials (HALT, MsFLASH, NCCTG, the NIH botanical center) mostly found no benefit over placebo for hot flashes.
-
The 2023 nonhormone therapy position statement of The North American Menopause Society.
The Menopause Society reviewed the evidence in 2023 and did not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy and certain prescription and behavioral treatments were the options it endorsed.
- Who
- position statement
- Dose
- n/a
- Duration
- n/a
- Result
- Supplements/herbal remedies not recommended for VMS (Level I–II); soy foods/extracts and equol not recommended (Level II); pollen extract (Level III), ammonium succinate, L. acidophilus, rhubarb (Level II); black cohosh (Level I), ginseng, vitamin E, Labisia (Level I); dong quai, EPO, maca, vitex, milk thistle, wild yam (Level II); omega-3 (Level III) – all not recommended.
- Funding
- The Menopause Society (formerly NAMS). Independent / academic
-
Effects of Withania somnifera root extract on sleep quality, body composition, and menopausal symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled trial.
66 Indian postmenopausal women took ashwagandha 600 mg a day or placebo for 12 weeks; sleep and menopause symptoms improved more with ashwagandha.
- Who
- 66 postmenopausal women (63 completed)
- Dose
- ashwagandha root extract 600 mg/day
- Duration
- 12 weeks
- Result
- Better sleep quality (PSQI -5.2 vs -0.8), menopause symptoms and body fat vs placebo; no BMD change.
- Funding
- No conflicts reported. Independent / academic
-
Complementary therapies for management of menopausal symptoms: a systematic review to inform the update of the International Menopause Society recommendations on women's midlife health.
A 2026 International Menopause Society evidence review rated black cohosh's benefit for hot flashes as moderate-certainty and most other supplements as low-certainty.
- Who
- 158 studies
- Dose
- various
- Duration
- n/a
- Result
- Moderate-certainty evidence supports black cohosh for vasomotor/menopausal symptoms and vitamin D for fracture risk; most complementary therapies low/very-low certainty.
- Funding
- International Menopause Society review. Independent / academic
-
Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study.
80 women took OLLY's EstroG-100 + GABA product or placebo for 5 weeks. Hot flashes, sleep and mood improved more than placebo. The study was run by the company that sells the product.
- Who
- 80 women
- Dose
- EstroG-100 514 mg + GABA 50 mg (OLLY Mellow Menopause)
- Duration
- 5 weeks
- Result
- Hot-flash intensity and number fell vs placebo from days 1–2; sleep, mood and sexual function improved at later time points.
- Funding
- Authors are employees of OLLY PBC, the product's manufacturer. Industry-linked
-
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.
In German medical records, women prescribed ERr 731 were not more likely to be diagnosed with breast cancer than women who were not. This is observational, partly industry-linked data.
- Who
- 5,686 users vs 17,058 non-users (German records)
- Dose
- ERr 731 prescriptions
- Duration
- observational
- Result
- No increase in breast-cancer diagnosis (OR 1.01, 95% CI 0.81–1.26).
- Funding
- Two authors employed by Health Research Services GmbH. Industry-linked
-
A prospective, randomized, double-blind, placebo-controlled study on efficacy and safety of Ashwagandha root extract (Withania somnifera) for managing menopausal symptoms in women.
60 Indian women took ashwagandha root extract or placebo for 8 weeks; symptoms, hot flashes and stress improved more with ashwagandha. Small and short.
- Who
- 60 women aged 45–55
- Dose
- ashwagandha root extract
- Duration
- 56 days
- Result
- MRS, hot-flash events and stress scores improved vs placebo.
- Funding
- Authors declared no conflicts. Independent / academic
-
Effects of collagen-based supplements on skin's hydration and elasticity: A systematic review and meta-analysis.
Pooling 10 trials, collagen supplements (about 3–4 g a day) improved skin hydration and elasticity more than placebo. Study quality was often unclear.
- Who
- 10 RCTs, 646 participants
- Dose
- median 3.5 g/day collagen
- Duration
- various
- Result
- Skin hydration SMD 1.25 and elasticity SMD 0.61 vs placebo; risk of bias mostly unclear.
- Funding
- Academic (Indonesia). Independent / academic
-
The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patch.
In women already using an estrogen patch, those also taking DIM had clearly different estrogen breakdown products in urine, raising the possibility that DIM could interfere with hormone therapy. There are no trials showing DIM relieves menopause symptoms.
- Who
- postmenopausal women on transdermal estradiol (observational)
- Dose
- DIM supplement
- Duration
- cross-sectional
- Result
- DIM significantly altered 6 of 10 urinary estrogen metabolites; may blunt hormone therapy.
- Funding
- Not stated in abstract. Funding not stated
-
The efficacy of purified pollen extract for reducing vasomotor symptoms in women: a systematic review and meta-analysis.
Researchers pooled every study of the pollen extract in Relizen. Women improved over 3 months, but when compared with placebo the difference disappeared, suggesting much of the benefit may be placebo. No significant side effects were seen.
- Who
- 5 studies (1 RCT + 4 observational), 420 women
- Dose
- purified cytoplasm of pollen (PureCyTonin/Relizen)
- Duration
- 3 months
- Result
- Large improvements before-vs-after, but when only controlled studies were pooled the effect was not statistically significant – may be placebo effect.
- Funding
- Authors reported no conflicts. Independent / academic
-
A prospective, multicenter, randomized, double-blind placebo-controlled trial on purified and specific Cytoplasmic pollen extract for hot flashes in breast cancer survivors.
39 breast-cancer survivors took the Relizen pollen ingredient or placebo for 3 months. Hot flashes fell in the active group, but the trial was very small and mainly compared women to their own starting point.
- Who
- 39 breast-cancer survivors
- Dose
- PureCyTonin (Relizen/Sérélys ingredient)
- Duration
- 3 months
- Result
- Fewer diary hot flashes vs baseline (P=.02) in the active group; well tolerated.
- Funding
- Not stated in abstract. Funding not stated
-
Estro G-100 herbal extract and hot flashes in postmenopausal women: A randomized double-blinded controlled trial.
In Iran, postmenopausal women took EstroG-100 or placebo; only 70 of 120 were analyzed. By week 6 the EstroG-100 group reported fewer hot flashes. The high drop-out rate weakens the result.
- Who
- 120 randomized, 70 analyzed (Iran)
- Dose
- EstroG-100 daily
- Duration
- 12 weeks (results reported at weeks 3–6)
- Result
- Fewer mild, moderate and severe hot flashes vs control at week 6 (P<.001).
- Funding
- Not stated in abstract. Funding not stated
-
Efficacy evaluation of standardized Rheum rhaponticum root extract (ERr 731 (®)) on symptoms of menopause: A systematic review and meta-analysis study.
A pooled analysis of 4 ERr 731 studies found large symptom reductions, but the analysis was written by staff of a company that sells the extract.
- Who
- 4 studies, 390 women
- Dose
- ERr 731
- Duration
- 12 weeks
- Result
- Pooled MRS reduction -15.1 points vs control (P<.001).
- Funding
- Lead authors from Sundyota Numandis (Indian distributor) – industry-affiliated. Industry-linked
-
Evening Primrose Oil for Menopause Hot Flashes: Systematic Review and Meta-Analysis.
A 2024 review concluded evidence is insufficient: evening primrose oil may ease hot-flash intensity slightly but does not reduce how often they happen.
- Who
- systematic review/MA
- Dose
- EPO
- Duration
- <6 months
- Result
- Lower severity vs placebo; no difference in frequency or duration; evidence insufficient.
- Funding
- Academic. Independent / academic
-
Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss: A Randomized Clinical Trial.
239 Swedish women took a probiotic or placebo for 2 years. The probiotic did not slow bone loss.
- Who
- 239 early-postmenopausal women
- Dose
- Limosilactobacillus reuteri 6475 (2 doses)
- Duration
- 2 years
- Result
- No effect on bone loss or bone turnover vs placebo.
- Funding
- Industry partner BioGaia (strain owner) per paper (not verified in abstract); independent stats. Industry-linked
-
Effects of probiotic supplementation on bone health in postmenopausal women: a systematic review and meta-analysis.
Pooling 12 trials, probiotics were linked to slightly better bone density in postmenopausal women, though the largest single trial was negative.
- Who
- 12 RCTs, 1,183 women
- Dose
- various probiotics
- Duration
- various
- Result
- Higher spine (SMD 0.60) and hip BMD (SMD 0.74) vs control.
- Funding
- Academic (China). Independent / academic
-
Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen(®) and Smart B(®) in Women with Climacteric Syndrome in Perimenopause.
106 women took Amberen with a companion product, with no placebo group. Symptoms improved over the study, but without a comparison group this cannot show the product caused the change.
- Who
- 106 perimenopausal women (open-label, no placebo)
- Dose
- Amberen + Smart B
- Duration
- per paper
- Result
- Greene, anxiety, depression and well-being scores improved from baseline.
- Funding
- Not stated in abstract (product study). Funding not stated
-
Black cohosh extracts in women with menopausal symptoms: an updated pairwise meta-analysis.
A 2023 analysis of 22 studies (about 2,300 women) found black cohosh extracts did somewhat better than placebo for overall menopause symptoms and hot flashes, with a small-to-moderate effect. It did not help anxiety or low mood, and the studies varied a lot in product and quality.
- Who
- 22 articles, 2,310 women
- Dose
- various black cohosh extracts
- Duration
- various
- Result
- Pooled improvement vs placebo in overall menopausal symptoms (Hedges g 0.58) and hot flashes (g 0.32); no significant effect on anxiety or depression.
- Funding
- Academic; one author reported speaker fees from supplement/pharma companies incl. Cimic. Some author ties
-
The Effect of Salvia Officinalis on Hot Flashes in Postmenopausal Women: A Systematic Review and Meta-Analysis.
A small review of 4 sage studies did not find a statistically clear reduction in hot flashes overall.
- Who
- 4 studies, 310 women
- Dose
- Salvia officinalis
- Duration
- various
- Result
- Hot-flash frequency effect not significant (ES -1.12, CI -2.37 to 0.14); severity NS.
- Funding
- Academic (Iran). Independent / academic
-
Oral administration of hyaluronic acid to improve skin conditions via a randomized double-blind clinical test.
A Chinese trial found oral hyaluronic acid improved skin hydration within weeks. Small and not focused on menopause.
- Who
- young and older adults (RCT)
- Dose
- oral HA
- Duration
- 12 weeks
- Result
- Hydration improved from 2–8 weeks; epidermal thickness up at 12 weeks.
- Funding
- Not stated in abstract. Funding not stated
-
Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence.
This review looked only at the specific black cohosh extract in Remifemin and found it beat placebo for menopause symptoms, especially at higher doses or combined with St John's wort. Several authors work for the company that makes Remifemin, so read it as a manufacturer-backed summary.
- Who
- 35 studies + 1 MA, 43,759 women (13,096 on iCR)
- Dose
- isopropanolic extract (iCR, Remifemin), 20–>40 mg/day
- Duration
- various
- Result
- SMD -0.69 vs placebo for neurovegetative/psychological symptoms; larger effect at higher dose and with St John's wort; no hepatotoxicity signal in trial data.
- Funding
- Co-authored by staff of Schaper & Brümmer (maker of Remifemin) – manufacturer-affiliated. Industry-linked
-
Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Pooling 8 trials, red clover reduced hot flashes by about 1–2 a day more than placebo, mostly in women with frequent hot flashes taking higher doses.
- Who
- 8 trials (10 comparisons)
- Dose
- red clover isoflavones
- Duration
- ~12 weeks
- Result
- -1.73 hot flushes/day vs placebo (95% CI -3.28 to -0.18), mainly in women with ≥5/day and ≥80 mg isoflavones.
- Funding
- Authors declared no conflicts. Independent / academic
-
Effect of an ashwagandha (Withania Somnifera) root extract on climacteric symptoms in women during perimenopause: A randomized, double-blind, placebo-controlled study.
100 Indian women in perimenopause took ashwagandha root extract (300 mg twice a day) or placebo for 8 weeks. Menopause symptoms and quality of life improved more with ashwagandha, and hormone levels shifted. The study was short and not yet repeated outside India.
- Who
- 100 perimenopausal women (91 completed)
- Dose
- ashwagandha root extract 300 mg twice daily
- Duration
- 8 weeks
- Result
- Total MRS and MENQoL improved vs placebo; estradiol up, FSH/LH down.
- Funding
- Not stated in abstract; Indian investigators (ingredient-supplier funding typical but not verified). Funding not stated
-
The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study.
86 Australian women in perimenopause took saffron extract or placebo for 12 weeks. Mood and anxiety improved more with saffron, but hot flashes did not. The saffron supplier funded the study.
- Who
- 86 perimenopausal women
- Dose
- saffron extract (affron) 14 mg twice daily
- Duration
- 12 weeks
- Result
- Improved psychological symptoms (anxiety -33%, depression -32%) vs placebo; no effect on hot flashes.
- Funding
- Funded by Pharmactive Biotech (affron maker). Industry-linked
-
Effectiveness of Menosan® Salvia officinalis in the treatment of a wide spectrum of menopausal complaints. A double-blind, randomized, placebo-controlled, clinical trial.
80 Swiss women took a fresh sage extract or placebo for 4 weeks. Menopause scores and hot flashes improved more with sage. The manufacturer sponsored the study, and 4 weeks is short.
- Who
- 80 women aged 48–65
- Dose
- Menosan sage (3,400 mg fresh-leaf ethanolic extract)
- Duration
- 4 weeks
- Result
- MRS -39% (P=.002 vs placebo); hot-flush severity -55% from week 3.
- Funding
- Sponsored by A. Vogel (manufacturer); author employee. Industry-linked
-
Oral Hyaluronan Relieves Wrinkles and Improves Dry Skin: A 12-Week Double-Blinded, Placebo-Controlled Study.
40 Asian adults took 120 mg hyaluronic acid or placebo for 12 weeks; wrinkles and skin dryness improved more with HA. Small, not menopause-specific.
- Who
- 40 adults aged 35–64
- Dose
- oral hyaluronic acid 120 mg/day
- Duration
- 12 weeks
- Result
- Wrinkles, skin water content and elasticity improved vs placebo.
- Funding
- Not stated in abstract (Kewpie HA ingredient typical; not verified). Funding not stated
-
Actaea racemosa L. Is More Effective in Combination with Rhodiola rosea L. for Relief of Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study.
220 women in Georgia took black cohosh alone, black cohosh plus Rhodiola, or placebo for 12 weeks; the combination worked best. An author is paid by the company that sells the combination.
- Who
- 220 women
- Dose
- black cohosh 6.5 mg; black cohosh 500 mg; Rhodiola+black cohosh (Menopause Relief EP); placebo
- Duration
- 12 weeks
- Result
- Rhodiola+black cohosh beat black cohosh alone and placebo on all symptom scales.
- Funding
- Author has contract with Europharma USA (seller) and heads Phytomed AB. Industry-linked
-
The Effect of Lactobacillus acidophilus YT1 (MENOLACTO) on Improving Menopausal Symptoms: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
67 Korean women took a specific probiotic strain or placebo for 12 weeks; overall menopause scores improved. It is the only trial of its kind and NAMS did not recommend it.
- Who
- 67 women (Korea)
- Dose
- Lactobacillus acidophilus YT1 (MENOLACTO) 1×10^8 CFU/day
- Duration
- 12 weeks
- Result
- Kupperman Index and MENQOL improved vs placebo; no hormone or endometrial changes.
- Funding
- Authors declared no conflicts. Independent / academic
-
Equol Decreases Hot Flashes in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
An analysis of 6 trials found S-equol lowered hot-flash scores overall, but 2 of the 5 pooled trials found no benefit and most trials were small.
- Who
- 6 RCTs, 779 women
- Dose
- S-equol or isoflavones in equol producers
- Duration
- various
- Result
- Pooled benefit on hot-flash scores; 3 of 5 trials positive, 2 null.
- Funding
- Academic (Korea); not stated as industry funded. Independent / academic
-
Succinate-Based Dietary Supplement for Menopausal Symptoms: A Pooled Analysis of Two Identical Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
Two identical 90-day Russian trials (227 women) were pooled; Amberen beat placebo on many menopause symptoms. Both trials are manufacturer-linked and have not been repeated independently.
- Who
- 227 women (pooled 2 identical RCTs)
- Dose
- Amberen
- Duration
- 90 days
- Result
- 16 of 21 Greene symptoms improved vs placebo; anxiety down; weight and waist reduced; estradiol rose.
- Funding
- Manufacturer-linked: an author is a paid consultant to Biogix (formerly Lunada Biomedical, Amberen's maker). Industry-linked
-
Multivessel Spontaneous Coronary Artery Dissection: Amberen as a Possible Risk Factor.
A single case report described a rare heart-artery tear in a woman taking Amberen. One case cannot prove cause, but it is worth knowing.
- Who
- 1 case
- Dose
- Amberen
- Duration
- n/a
- Result
- Case of multivessel spontaneous coronary artery dissection possibly linked to Amberen.
- Funding
- Case report. Independent / academic
-
Soy and isoflavones consumption and breast cancer survival and recurrence: a systematic review and meta-analysis.
Studies following women with breast cancer found eating soy was linked to lower recurrence, not higher. These looked at soy food, not concentrated supplements.
- Who
- 12 cohort studies, 37,275 breast-cancer patients
- Dose
- dietary soy/isoflavone intake
- Duration
- observational
- Result
- Pre- and post-diagnosis soy intake associated with lower recurrence; no harm signal.
- Funding
- Academic. Independent / academic
-
Comparison of Vitex agnus-castus Extracts with Placebo in Reducing Menopausal Symptoms: A Randomized Double-Blind Study.
52 Iranian women took chasteberry or placebo for 8 weeks; symptom questionnaires improved more with vitex. Small and questionnaire-based.
- Who
- 52 women (Iran)
- Dose
- Vitex agnus-castus extract
- Duration
- 8 weeks
- Result
- Total menopausal, anxiety and vasomotor scores lower vs placebo.
- Funding
- No conflicts reported. Independent / academic
-
Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for menopausal women: A systematic review of clinical trials and the way forward.
A review of all Pueraria mirifica studies found they were small, poorly designed and used unstandardized products, so it is unknown whether it works. Its estrogen-like compounds are strong, which raises safety questions.
- Who
- 8 studies, 309 women
- Dose
- various P. mirifica doses
- Duration
- various
- Result
- Symptom scores fell ~50% from baseline, but studies had high risk of bias, undefined active ingredients and no standardization; CRP doubled.
- Funding
- Academic (Thailand). Independent / academic
-
Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial.
60 Iranian women with depression and hot flashes took saffron (30 mg a day) or placebo for 6 weeks; both mood and hot-flash bother improved more with saffron. Small and short.
- Who
- 60 postmenopausal women with depression and hot flashes
- Dose
- saffron 15 mg twice daily
- Duration
- 6 weeks
- Result
- Hot-flash interference and depression scores improved vs placebo.
- Funding
- Academic (Iran). Independent / academic
-
Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: US Preventive Services Task Force Recommendation Statement.
The US Preventive Services Task Force says low-dose calcium and vitamin D do not prevent fractures in healthy postmenopausal women living at home, and evidence for higher doses is insufficient.
- Who
- USPSTF review
- Dose
- ≤400 IU vit D, ≤1,000 mg calcium
- Duration
- n/a
- Result
- Recommends against these low doses for primary fracture prevention in community-dwelling postmenopausal women; insufficient evidence for higher doses; kidney-stone harm.
- Funding
- USPSTF (independent US federal panel). Independent / academic
-
Statement on the safety of EstroG-100™ as a novel food pursuant to Regulation (EC) No 258/97.
Europe's food-safety agency approved EstroG-100 only up to 175 mg a day – about a third of the dose used in many US products and trials – because of limited long-term safety data.
- Who
- n/a (EU safety opinion)
- Dose
- max 175 mg/day judged safe
- Duration
- n/a
- Result
- EFSA considered EstroG-100 safe at 175 mg/day in postmenopausal women (lower than the 514 mg/day proposed) because of liver/blood findings in animal studies and limited human data.
- Funding
- EFSA (independent EU regulator). Independent / academic
-
Efficacy of a Proprietary Trigonella foenum-graecum L. De-Husked Seed Extract in Reducing Menopausal Symptoms in Otherwise Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Study.
115 Australian women took fenugreek seed extract (600 mg a day) or placebo for 12 weeks; hot flashes, night sweats and quality of life improved more with fenugreek.
- Who
- 115 women aged 40–65
- Dose
- fenugreek de-husked seed extract 600 mg/day
- Duration
- 12 weeks
- Result
- MENQOL and day/night hot flushes improved vs placebo (P<.001); estradiol unchanged.
- Funding
- Conducted by BRIDI Centre (contract research); sponsor (ingredient supplier) not stated in abstract. Industry-linked
-
Treatment of climacteric symptoms with an ammonium succinate-based dietary supplement: a randomized, double-blind, placebo-controlled trial.
125 Russian women took Amberen or placebo for 3 months. Many symptom scores and anxiety improved more on Amberen. NAMS notes this research was paid for by the manufacturer.
- Who
- 125 women aged 42–60
- Dose
- Amberen (ammonium succinate-based)
- Duration
- 3 months
- Result
- Improvement in 13 of 21 Greene symptoms vs placebo; reduced anxiety; estradiol/leptin changes, weight loss.
- Funding
- Not stated in abstract; manufacturer-sponsored per NAMS 2023. Industry-linked
-
Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.
A JAMA analysis of 62 studies found plant estrogens such as soy cut about one hot flash a day compared with placebo – a modest effect – and most studies were of low quality.
- Who
- 62 studies, 6,653 women
- Dose
- phytoestrogens and other plant therapies
- Duration
- various
- Result
- Phytoestrogens: -1.31 hot flashes/day; soy isoflavones -0.79/day; 74% of RCTs at high risk of bias.
- Funding
- Academic (Erasmus MC); industry co-funding reported in paper is not verified here. Industry-linked
-
The effect of Hop (Humulus lupulus L.) on early menopausal symptoms and hot flashes: A randomized placebo-controlled trial.
120 Iranian women took hops or placebo for 12 weeks and reported fewer hot flashes with hops. One unreplicated study.
- Who
- 120 women (Iran)
- Dose
- hop tablets
- Duration
- 12 weeks
- Result
- Greene score and hot-flash counts lower vs placebo at weeks 4, 8, 12.
- Funding
- Academic (Tabriz Univ.). Independent / academic
-
Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation.
A meta-analysis of 8 trials (31,000 people) found calcium plus vitamin D lowered fracture risk by about 15% overall and hip fractures by about 30%.
- Who
- 8 RCTs, 30,970 people
- Dose
- calcium + vitamin D
- Duration
- various
- Result
- Total fractures -15% (RR 0.85), hip fractures -30% (RR 0.70).
- Funding
- National Osteoporosis Foundation analysis; funding source not verified here. Funding not stated
-
A Novel Extract of Fenugreek Husk (FenuSMART™) Alleviates Postmenopausal Symptoms and Helps to Establish the Hormonal Balance: A Randomized, Double-Blind, Placebo-Controlled Study.
88 Indian women took a branded fenugreek extract or placebo; symptoms improved and estradiol rose. The ingredient maker ran the study.
- Who
- 88 women
- Dose
- fenugreek husk extract (FenuSMART) 1,000 mg/day
- Duration
- 90 days
- Result
- Estradiol +120%; symptoms and QoL improved vs placebo.
- Funding
- Authors from Akay Flavours (ingredient maker). Industry-linked
-
North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.
289 women who had breast cancer took magnesium (800 or 1,200 mg a day) or placebo. Magnesium did not reduce hot flashes and caused more diarrhea.
- Who
- 289 women with breast-cancer history
- Dose
- magnesium oxide 800 or 1,200 mg/day
- Duration
- 8 weeks (per protocol)
- Result
- No difference vs placebo in hot-flash score or frequency; more diarrhea.
- Funding
- NCI/Alliance cooperative group (public). Independent / academic
-
Black cohosh and breast cancer: a systematic review.
A systematic review of black cohosh and breast cancer found no sign it increases breast-cancer risk, but also no proof it reduces hot flashes in women who have had breast cancer.
- Who
- 26 studies (14 RCTs)
- Dose
- various
- Duration
- various
- Result
- No evidence black cohosh raises breast-cancer risk; no proven hot-flash benefit in breast-cancer patients vs placebo.
- Funding
- Academic (Canadian naturopathic/academic group). Independent / academic
-
Red clover extract for alleviating hot flushes in postmenopausal women: a meta-analysis.
A review found red clover modestly reduced hot flashes over 3–4 months, but the benefit was no longer seen at 12 months.
- Who
- meta-analysis
- Dose
- red clover extract
- Duration
- 3–4 months and 12 months
- Result
- Effective at 3–4 months (MD -1.34/day) but not at 12 months.
- Funding
- Academic (Monash). Independent / academic
-
Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis.
Women aged 45–65 took 2.5 g of a specific collagen peptide or placebo for 8 weeks; eye wrinkles decreased about 20% more than placebo.
- Who
- 114 women aged 45–65
- Dose
- bioactive collagen peptides 2.5 g/day (Verisol)
- Duration
- 8 weeks
- Result
- Eye-wrinkle volume -20% vs placebo; procollagen I +65%, elastin +18%.
- Funding
- Industry-linked (collagen-peptide supplier) – not verified in abstract. Industry-linked
-
Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
In a large NIH-funded US trial, 355 women took omega-3 fish oil or placebo for 12 weeks. Omega-3 did not reduce hot flashes or improve sleep or mood.
- Who
- 355 women (MsFLASH)
- Dose
- omega-3 fish-oil capsules (EPA+DHA; exact dose per paper)
- Duration
- 12 weeks
- Result
- VMS frequency change -2.5 vs -2.7 placebo (P=.28); no effect on sleep or mood.
- Funding
- US NIH (MsFLASH network) – independent. Independent / academic
-
Phytoestrogens for menopausal vasomotor symptoms.
An independent Cochrane review of 43 trials found no conclusive proof that phytoestrogens (soy, red clover) reduce hot flashes. High-genistein soy extracts looked more promising, and placebo effects were large.
- Who
- 43 RCTs, 4,364 women
- Dose
- various phytoestrogens
- Duration
- various
- Result
- No conclusive evidence of reduced hot flushes; Promensil (red clover) not better than placebo (MD -0.93/day, NS); genistein >30 mg/day may help; strong placebo effect.
- Funding
- Cochrane review (independent). Independent / academic
-
The effect of oral evening primrose oil on menopausal hot flashes: a randomized clinical trial.
56 Iranian women took evening primrose oil or placebo for 6 weeks. Hot flashes became a bit less intense, but not less frequent.
- Who
- 56 women aged 45–59
- Dose
- EPO 2 × 500 mg/day
- Duration
- 6 weeks
- Result
- Only hot-flash severity improved more than placebo; frequency and duration did not.
- Funding
- Academic (Iran). Independent / academic
-
Effect of low-dose French maritime pine bark extract on climacteric syndrome in 170 perimenopausal women: a randomized, double-blind, placebo-controlled trial.
170 Japanese women took a low dose of French maritime pine bark extract (60 mg a day) or placebo for 12 weeks. Symptoms, especially hot flashes and sleep, improved more than placebo, though placebo also helped a lot.
- Who
- 170 perimenopausal women (Japan)
- Dose
- Pycnogenol 30 mg twice daily
- Duration
- 12 weeks
- Result
- Kupperman -56% vs -39% placebo (P<.05); hot flashes and sleep improved.
- Funding
- Not stated in abstract (Horphag Research, maker, typically supports Pycnogenol trials; not verified). Funding not stated
-
Black cohosh (Cimicifuga spp.) for menopausal symptoms.
An independent Cochrane review pooled 16 trials with about 2,000 women taking black cohosh (usually 40 mg a day for around 5 months). Women taking black cohosh did not have fewer hot flashes than women on a dummy pill, and the reviewers called the safety data inconclusive.
- Who
- 16 RCTs, 2,027 women
- Dose
- median 40 mg/day black cohosh extract
- Duration
- mean 23 weeks
- Result
- No difference vs placebo in hot-flush frequency (MD +0.07/day; 95% CI -0.43 to 0.56; 3 trials, 393 women) or symptom scores; hormone therapy beat black cohosh.
- Funding
- Cochrane review (independent). Independent / academic
-
The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study.
64 US women took EstroG-100 (a Korean 3-herb blend) or placebo for 12 weeks. Overall symptom scores, including hot flashes and vaginal dryness, improved much more than with placebo. It is one small study and has not been widely repeated.
- Who
- 64 women (US, multi-ethnic)
- Dose
- EstroG-100 daily
- Duration
- 12 weeks
- Result
- Kupperman Index 29.5→11.3 vs 29.2→23.7 placebo (P<.01); vaginal dryness improved.
- Funding
- Not stated in abstract (ingredient maker Naturalendo Tech is the developer; not verified). Funding not stated
-
A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women.
160 Japanese women who could not make equol themselves took 10 mg S-equol or placebo for 12 weeks. Hot flashes fell about 59% vs 35% on placebo. The ingredient's maker ran the research, and Japanese women tend to have milder hot flashes than US women.
- Who
- 160 Japanese equol non-producers (126 completed)
- Dose
- natural S-equol 10 mg/day
- Duration
- 12 weeks
- Result
- Hot flushes -58.7% vs -34.5% placebo (P=.009); less neck/shoulder stiffness.
- Funding
- Otsuka Pharmaceutical (developer of the S-equol ingredient used in Equelle). Industry-linked
-
A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency.
The only US hot-flash trial of S-equol compared different doses with soy isoflavones, with no placebo group. All groups improved similarly; higher doses did slightly better. It was run by Pharmavite, which makes Equelle.
- Who
- 102 US postmenopausal women
- Dose
- S-equol 10, 20 or 40 mg/day vs soy isoflavones (no placebo)
- Duration
- 8 weeks
- Result
- Similar hot-flash reductions at week 8; 40 mg beat isoflavones on cumulative analysis; 10–20 mg better for muscle/joint pain.
- Funding
- Pharmavite LLC (Equelle maker) – lead author employee. Industry-linked
-
Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials.
Pooling 17 trials, soy isoflavone supplements (about 54 mg a day) cut hot-flash frequency by about a fifth more than placebo. Products higher in genistein worked better. Results varied widely between studies.
- Who
- 17 RCTs in meta-analysis
- Dose
- median 54 mg isoflavones/day
- Duration
- 6 weeks–12 months
- Result
- Hot-flash frequency -20.6% and severity -26.2% vs placebo; >18.8 mg genistein about twice as effective.
- Funding
- Academic (Japan/US); funding not stated in abstract. Funding not stated
-
Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract.
This analysis of 5 trials found no change in liver blood tests in women taking the Remifemin extract for up to 6 months. It was written by the manufacturer and covers only short-term use.
- Who
- 5 RCTs, 1,117 women
- Dose
- iCR 40–128 mg/day
- Duration
- 3–6 months
- Result
- No effect on liver enzymes (AST/ALT) vs reference groups.
- Funding
- Written by Schaper & Brümmer (Remifemin maker) staff. Industry-linked
-
Maca (Lepidium meyenii) for treatment of menopausal symptoms: A systematic review.
A review found only 4 small trials of maca for menopause; all were positive but too weak to be convincing.
- Who
- 4 RCTs
- Dose
- maca, various
- Duration
- various
- Result
- All 4 showed favorable effects, but trials were few, small and of limited quality.
- Funding
- Academic (Korea/UK). Independent / academic
-
First time proof of sage's tolerability and efficacy in menopausal women with hot flushes.
In a study without a placebo group, women taking fresh sage had 64% less hot-flash intensity after 8 weeks. Without placebo comparison this cannot separate sage from placebo effect.
- Who
- 71 women (single arm, no placebo)
- Dose
- fresh sage leaf tablet once daily
- Duration
- 8 weeks
- Result
- Hot-flush intensity score -50% at 4 weeks, -64% at 8 weeks vs baseline.
- Funding
- Not stated in abstract (manufacturer product). Funding not stated
-
A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts.
36 Finnish women took a hop extract and placebo for 8 weeks each. Overall it did not beat placebo.
- Who
- 36 women (crossover)
- Dose
- standardized hop extract
- Duration
- 16 weeks (8+8)
- Result
- No significant overall effect; some time-specific improvements.
- Funding
- Not stated in abstract. Funding not stated
-
Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.
In a year-long, government-funded trial, women took black cohosh, red clover, hormone therapy or a dummy pill. Only hormones beat placebo for hot flashes; both herbs looked safe but did not reduce hot flashes more than placebo.
- Who
- 89 women (4 arms)
- Dose
- standardized black cohosh and red clover extracts vs CEE/MPA vs placebo
- Duration
- 12 months
- Result
- Hot-flash reduction: black cohosh 34%, red clover 57%, placebo 63%, hormones 94%; neither botanical beat placebo. Both appeared safe over 12 months.
- Funding
- NIH (NCCAM/ODS) botanical center, University of Illinois – independent. Independent / academic
-
Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms.
A second 12-week trial by the same research group (112 women) again found large improvements with ERr 731 versus placebo. Independent replication is still lacking.
- Who
- 112 perimenopausal women
- Dose
- ERr 731 one tablet/day
- Duration
- 12 weeks
- Result
- MRS total 27.0→12.4 vs 27.0→24.0 placebo (P<.0001); hot flushes reduced.
- Funding
- Same research group as the original trial; funding not stated in abstract. Industry-linked
-
Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.
120 Canadian women took an EPA fish-oil supplement or placebo for 8 weeks; hot flashes fell by about one more per day. A larger later trial did not confirm this.
- Who
- 120 women with psychological distress (Canada)
- Dose
- ethyl-EPA (per NAMS: 1,100 mg EPA + 50 mg DHA)
- Duration
- 8 weeks
- Result
- Hot flashes -1.58/day vs -0.50/day placebo.
- Funding
- Not stated in abstract. Funding not stated
-
Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial.
100 Australian women took a St John's wort + chasteberry combination or placebo for 16 weeks. It did not beat placebo – the largest, most rigorous vitex trial.
- Who
- 100 women
- Dose
- St John's wort + Vitex combination
- Duration
- 16 weeks
- Result
- No difference vs placebo for hot flushes, Greene scale or depression.
- Funding
- Academic (Australia). Independent / academic
-
United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.
The US Pharmacopeia reviewed 30 reports of liver injury in people using black cohosh. It could not prove black cohosh caused them but recommended a label warning to stop and see a doctor if liver symptoms appear.
- Who
- 30 case reports of liver damage
- Dose
- various products
- Duration
- n/a
- Result
- All 30 liver cases rated 'possible' (none probable/certain); USP recommended a cautionary liver label.
- Funding
- US Pharmacopeia expert committee (independent standard-setter). Independent / academic
-
Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content.
14 women took maca powder (3.5 g a day) and placebo for 6 weeks each. Mood and sexual-function scores improved on maca without changing hormones. Very small.
- Who
- 14 postmenopausal women (crossover)
- Dose
- maca 3.5 g/day
- Duration
- 6 weeks each arm
- Result
- Lower anxiety, depression and sexual-dysfunction scores vs placebo; no hormone changes.
- Funding
- Not stated in abstract. Funding not stated
-
Effect of Pueraria mirifica on vaginal health.
71 Thai postmenopausal women took Pueraria mirifica or placebo for 24 weeks. Vaginal dryness improved and vaginal tissue showed estrogen-like changes – evidence that it acts like a hormone.
- Who
- 71 women (51 PM, 20 placebo)
- Dose
- P. mirifica, 3 doses
- Duration
- 24 weeks
- Result
- Less vaginal dryness; vaginal cells shifted toward an estrogen-stimulated pattern.
- Funding
- Not stated in abstract. Funding not stated
-
A randomised, double-blind, placebo-controlled trial on the effect of Pycnogenol on the climacteric syndrome in peri-menopausal women.
About 200 Taiwanese women took 200 mg pine bark extract or placebo for 6 months, and symptoms improved more with the extract.
- Who
- 200 enrolled, 155 completed (Taiwan)
- Dose
- Pycnogenol 200 mg/day
- Duration
- 6 months
- Result
- All climacteric symptoms improved vs placebo; antioxidant status improved.
- Funding
- Not stated in abstract. Funding not stated
-
Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone.
244 Chinese women took Remifemin-type black cohosh or the hormone-like drug tibolone for 12 weeks. Symptom scores fell similarly in both groups, but there was no placebo group, so the size of the true effect is unclear.
- Who
- 244 Chinese women
- Dose
- iCR (Remifemin) equivalent to 40 mg/day vs tibolone 2.5 mg/day (no placebo)
- Duration
- 12 weeks
- Result
- Kupperman Index fell similarly with iCR and tibolone; iCR better tolerated.
- Funding
- Not stated in abstract. Funding not stated
-
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.
In a publicly funded US trial, 132 women took black cohosh (20 mg twice a day) or placebo for 4 weeks each. Hot flashes dropped slightly more on placebo than on black cohosh, so the trial found no benefit.
- Who
- 132 women (history of or concern about breast cancer; crossover)
- Dose
- black cohosh 20 mg twice daily
- Duration
- two 4-week periods (crossover)
- Result
- Hot-flash frequency fell 17% on black cohosh vs 26% on placebo (P=.36) – no benefit.
- Funding
- NCCTG/NCI cooperative group (public funding). Independent / academic
-
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.
The US government-funded HALT study followed 351 women for a year. Black cohosh (160 mg a day), a 10-herb blend, and the blend plus more soy food did no better than a dummy pill for hot flashes, while hormone therapy clearly worked.
- Who
- 351 women aged 45–55
- Dose
- black cohosh 160 mg/day; multibotanical; multibotanical + soy diet; hormone therapy; placebo
- Duration
- 12 months
- Result
- No herbal arm differed from placebo at 3, 6 or 12 months (<1 hot flash/day difference); hormone therapy reduced ~4 symptoms/day vs placebo.
- Funding
- US NIH (NCCAM/NIA) – HALT study, independent. Independent / academic
-
Black cohosh and St. John's wort for climacteric complaints: a randomized trial.
301 women with menopause symptoms and low mood took a black cohosh + St John's wort combination or placebo for 16 weeks. Symptoms and mood improved much more on the combination. St John's wort interacts with many medicines, including birth control and blood thinners.
- Who
- 301 women with psychological symptoms
- Dose
- iCR black cohosh + St John's wort fixed combination
- Duration
- 16 weeks
- Result
- Menopause Rating Scale fell 50% vs 19.6% with placebo; depression score fell 41.8% vs 12.7% (both P<.001).
- Funding
- Not stated in abstract (manufacturer product, Remifemin plus). Funding not stated
-
Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial.
109 perimenopausal women took the rhubarb-root extract ERr 731 (sold as Estrovera/Estroven Complete) or placebo for 12 weeks. Symptoms including hot flashes improved strongly. However, most women on placebo dropped out, which makes the comparison less reliable.
- Who
- 109 perimenopausal women
- Dose
- ERr 731 one tablet/day (4 mg)
- Duration
- 12 weeks
- Result
- MRS total and each symptom improved vs placebo (P<.0001); fewer and milder hot flushes from week 4; no endometrial changes. NAMS notes only 7/55 placebo completers.
- Funding
- Authors from Health Research Services Ltd; manufacturer (Dr. Loges) funding not stated in abstract. Industry-linked
-
A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts.
67 Belgian women took a hop extract or placebo for 12 weeks. There was an early benefit at 6 weeks that was no longer significant at 12 weeks.
- Who
- 67 women
- Dose
- hop extract 100 or 250 µg 8-PN/day
- Duration
- 12 weeks
- Result
- 100 µg beat placebo at 6 weeks but not 12 weeks; no dose-response.
- Funding
- Not stated in abstract. Funding not stated
-
Calcium plus vitamin D supplementation and the risk of fractures.
In the huge Women's Health Initiative, 36,000 women took calcium plus vitamin D or placebo for about 7 years. Bone density improved slightly, but fractures were not significantly reduced overall, and kidney stones were a bit more common.
- Who
- 36,282 women aged 50–79 (WHI)
- Dose
- calcium 1,000 mg + vitamin D3 400 IU/day
- Duration
- mean 7 years
- Result
- Hip BMD +1.06%; no significant reduction in hip (HR 0.88) or total fractures (HR 0.96); kidney stones increased (HR 1.17).
- Funding
- US NIH (NHLBI) – Women's Health Initiative. Independent / academic
-
Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.
About 300 women with menopause symptoms took Remifemin-type black cohosh (40 mg a day) or a dummy pill for 12 weeks. Symptom scores improved more with black cohosh, mostly in women early in menopause, and side effects were similar to placebo.
- Who
- 304 women
- Dose
- iCR (Remifemin) equivalent to 40 mg root/day
- Duration
- 12 weeks
- Result
- More effective than placebo on the Menopause Rating Scale (P<.001), mainly in early menopause; hot-flush subscore was the most responsive.
- Funding
- Funding not stated in the abstract (study of the manufacturer's extract). Funding not stated
-
Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.
122 women took a different (ethanol-based) black cohosh extract or placebo for 12 weeks. Overall it did not beat placebo; only women with more severe symptoms seemed to benefit, which is a weaker, after-the-fact finding.
- Who
- 122 women with ≥3 hot flashes/day
- Dose
- dried ethanolic black cohosh extract (non-Remifemin)
- Duration
- 12 weeks
- Result
- No superiority over placebo overall; benefit only in subgroup with moderate–severe symptoms (Kupperman ≥20: -47% vs -21%).
- Funding
- Not stated in abstract. Funding not stated
-
Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study.
64 women took Femal flower-pollen extract or placebo for 3 months; 54 finished. Hot flashes fell more on the pollen extract, but this is a single small study.
- Who
- 64 randomized (54 completed)
- Dose
- Femal (pollen extract) 2 tablets/day
- Duration
- 3 months
- Result
- 65% responders vs 38% placebo (P<.006); diary hot flushes 27% lower vs placebo.
- Funding
- Not stated in abstract (Femal is a Natumin Pharma product). Funding not stated
-
Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study.
Italian women took high-dose soy isoflavones (150 mg a day) or placebo for 5 years. A small number on soy developed thickening of the womb lining (3.4% vs 0%), so long-term high doses deserve caution.
- Who
- 376 women with intact uterus
- Dose
- soy isoflavones 150 mg/day
- Duration
- 5 years
- Result
- Endometrial hyperplasia in 3.37% on soy vs 0% placebo; no cancers.
- Funding
- Not stated in abstract. Funding not stated
-
Effect of oral gamolenic acid from evening primrose oil on menopausal flushing
In the original UK trial (BMJ 1994), 56 women took evening primrose oil or placebo for 6 months; placebo actually did slightly better.
- Who
- 56 women
- Dose
- evening primrose oil 500 mg/day (gamolenic acid)
- Duration
- 6 months
- Result
- Hot flashes fell 1.0/day on EPO vs 2.6/day on placebo – no benefit (as summarized by NAMS 2023).
- Funding
- Not verified. Funding not stated
Note: Details as summarized in NAMS 2023 statement (url); original BMJ paper not opened. Unverified
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.